1. At a Glance
Ajanta Pharma pulled off a decent Q1 FY26 with Revenue ₹1,303 Cr (+13.8% YoY) and Net Profit ₹255 Cr (+3.9% YoY). Margins stayed strong at 27% OPM, proving it’s still a beast in niche generics despite pricing pressure.
2. Introduction
Imagine a pharma player that doesn’t chase blockbuster drugs but still keeps minting money. That’s Ajanta. With 24.9% ROE and zero debt drama, it’s the quiet overachiever of the pharma pack.
3. Business Model – WTF Do They Even Do?
- India (31% Rev): Branded generics in cardiology, ophthalmology, dermatology, pain management.
- Rest of the World: Africa branded generics, US generics, Asia formulations.
- Moat: First-to-market strategy (50% products 1st to market), 2800+ MRs, and consistent pipeline launches.
4. Financials Overview
- Q1 FY26 Revenue: ₹1,303 Cr
- Net Profit: ₹255
